This story has been updated from an earlier version to inlcude stock quotes and details of DNA Research Innovations' ChargeSwitch technology.
Invitrogen, which has made a name for itself as a hungry corporate acquirer, paid $35 million for the Kent, UK-based firm. Invitrogen may also give DNA Research as much as $30 million if certain undisclosed R&D milestones are met.
The deal gives Invitrogen control of the company's ChargeSwitch nucleic acid-purification technology, which can be used with either DNA or RNA in a range of formats, and includes manual purification of a few samples for high throughput automated applications, the companies said. The platform can be used in bacteria, tissues, blood, forensic sample and buccal cells.
ChargeSwitch does not require the use of caustic chemicals, and can be applied to surfaces such as magnetic beads, microtiter plates, columns, and cartridges. Invitrogen said it expects the platform to help it develop novel tailor-made purification strategies.
"We believe the advantages of [the] ChargeSwitch technology will provide researchers with a compelling reason to start their projects using Invitrogen products," Greg Lucier, Invitrogen's chairman and CEO, said in a statement.
DNA Research currently sells a number of purification kits in the
Invitrogen plans to release its third-quarter earnings after the market closes today.